Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion. (Q37774393)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20645987%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

review article

1 reference

title

Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20645987%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

Bruce H Wolffenbuttel

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20645987%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

author name string

Paul J W H Kappelle

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20645987%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Arie van Tol

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20645987%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Robin P F Dullaart

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20645987%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

publication date

14 July 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20645987%20AND%20SRC:MED&resulttype=core&format=json

Cardiovascular Therapeutics

8 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20645987%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20645987%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20645987%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

page(s)

e89-99

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20645987%20AND%20SRC:MED&resulttype=core&format=json

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

8 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

HDL as a target in the treatment of atherosclerotic cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

High-density lipoprotein as a therapeutic target: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

The end of the road for CETP inhibitors after torcetrapib?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

CETP inhibition in cardiovascular risk management: a critical appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

JTT-705: is there still future for a CETP inhibitor after torcetrapib?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

High-density lipoprotein: a fall from grace?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Inhibition of cholesteryl ester transfer protein activity: a new therapeutic approach to raising high-density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Common variation in the CETP gene and the implications for cardiovascular disease and its treatment: an updated analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Organization of the human cholesteryl ester transfer protein gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Genome-wide association analysis of high-density lipoprotein cholesterol in the population-based KORA study sheds new light on intergenic regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Genetic loci associated with plasma concentration of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A1, and Apolipoprotein B among 6382 white women in genome-wide analysis with replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Cholesteryl ester transfer protein (CETP) increases postprandial triglyceridaemia and delays triacylglycerol plasma clearance in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Metabolic origins and clinical significance of LDL heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

High-density lipoprotein particle size and concentration and coronary risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Molecular processes that handle -- and mishandle -- dietary lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Formation and Metabolism of Prebeta-Migrating, Lipid-Poor Apolipoprotein A-I

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Plasma pre beta-HDL formation is decreased by atorvastatin treatment in type 2 diabetes mellitus: Role of phospholipid transfer protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Apolipoprotein M predicts pre-beta-HDL formation: studies in type 2 diabetic and nondiabetic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Importance of different pathways of cellular cholesterol efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

The ability of plasma to stimulate fibroblast cholesterol efflux is associated with the -629C-->A cholesteryl ester transfer protein promoter polymorphism: role of lecithin: cholesterol acyltransferase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Cholesterol efflux from J774 macrophages and Fu5AH hepatoma cells to serum is preserved in CETP-deficient patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

The effects of cholesterol ester transfer protein inhibition on cholesterol efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Expression of cholesteryl ester transfer protein in human atherosclerotic lesions and its implication in reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

HDL and immunomodulation: an emerging role of HDL against atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Human cholesteryl ester transfer protein expression enhances the mouse survival rate in an experimental systemic inflammation model: a novel role for CETP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Assessment of cholesteryl ester transfer protein inhibitors for interaction with proteins involved in the immune response to infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Relationship of high-density lipoprotein subfractions and cholesteryl ester transfer protein in plasma to carotid artery wall thickness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Cholesteryl ester transfer protein, coronary calcium, and intima-media thickness of the carotid artery in middle-age Japanese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and nondiabetic subjects: role of CETP and triglycerides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Elevated cholesteryl ester transfer protein concentration is associated with an increased risk for cardiovascular disease in women, but not in men, with Type 2 diabetes: the Hoorn Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Cholesteryl ester transfer protein and atherosclerosis in Japanese subjects: a study based on coronary angiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

High plasma cholesteryl ester transfer protein levels may favour reduced incidence of cardiovascular events in men with low triglycerides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

High plasma lecithin:cholesterol acyltransferase activity does not predict low incidence of cardiovascular events: possible attenuation of cardioprotection associated with high HDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Cholesteryl ester transfer protein activity and cardiovascular events in patients with chronic kidney disease stage V.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

High HDL cholesterol does not protect against coronary artery disease when associated with combined cholesteryl ester transfer protein and hepatic lipase gene variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Effect of torcetrapib on the progression of coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosc

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Regulation of the scavenger receptor BI and the LDL receptor by activators of aldosterone production, angiotensin II and PMA, in the human NCI-H295R adrenocortical cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Mechanism of inhibition defines CETP activity: a mathematical model for CETP in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Safety and tolerability of dalcetrapib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Elevated HDL is a risk factor for recurrent coronary events in a subgroup of non-diabetic postinfarction patients with hypercholesterolemia and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Inflammation reduces HDL protection against primary cardiac risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

HDL: bridging past and present with a look at the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

High plasma C-reactive protein (CRP) is related to low paraoxonase-I (PON-I) activity independently of high leptin and low adiponectin in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

HDL as a biomarker, potential therapeutic target, and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Plasma lecithin: cholesterol acyltransferase activity modifies the inverse relationship of C-reactive protein with HDL cholesterol in nondiabetic men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X

Cholesteryl ester transfer protein: friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2010.00201.X